| Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. | |
| | |
MedLine Citation:
|
PMID: 21441574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. |
| | |
Authors:
|
Heinz Ludwig; Meral Beksac; Joan Bladé; Jamie Cavenagh; Michele Cavo; Michel Delforge; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Jean-Luc Harousseau; Urs Hess; Martin Kropff; Fernando Leal da Costa; Vernon Louw; Hila Magen-Nativ; Larisa Mendeleeva; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Pieter Sonneveld; Miklos Udvardy; Pia Sondergeld; Antonio Palumbo |
Related Documents
:
|
9086634 - Knowledge and power: a critique of an international relief operation. 10824 - Propoxyphene napsylate. 21302664 - Statistics at a glance. 16935744 - R&d technology investments: misguided and expensive or a better way to discover medicines? 12064184 - Nontraditional approaches to pain management. 19949554 - Factors associated with veterinarians' career path choices in the early postgraduate pe... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2011-03-26 |
Journal Detail:
|
Title: The oncologist Volume: 16 ISSN: 1549-490X ISO Abbreviation: Oncologist Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-04-18 Completed Date: 2011-09-15 Revised Date: 2012-04-25 |
Medline Journal Info:
|
Nlm Unique ID: 9607837 Medline TA: Oncologist Country: United States |
Other Details:
|
Languages: eng Pagination: 388-403 Citation Subset: IM |
Affiliation:
|
Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, Austria. heinz.ludwig@wienkav.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Boronic Acids / therapeutic use Comorbidity Congresses as Topic Disease-Free Survival Europe Evidence-Based Practice Humans Multiple Myeloma / drug therapy*, therapy* Pyrazines / therapeutic use Stem Cell Transplantation* Thalidomide / analogs & derivatives, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Boronic Acids; 0/Pyrazines; 0/bortezomib; 191732-72-6/lenalidomide; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: External quality assessment for KRAS testing is needed: setup of a European program and report of th...
Next Document: PlantMiRNAPred: efficient classification of real and pseudo plant pre-miRNAs.